TORONTO, November 11, 2022 /PRNewswire/ – TripSitter Clinic Ltd. (CSE: KETA) (FSE: UY0) (“TripSitter” or the “Company”), following the press release of the March 22, 2022, today announced the closing of the acquisition of the assets of Insight Systems, with PBC doing business as Reconscious Medical. Reconscious Medical’s assets will play a key role in the Company’s future growth plans.

Reconscious Medical is a psychedelic psychotherapy company that offers in-clinic and online virtual care with safety, monitoring and support delivered through a proprietary technology platform. To date, Reconscious Medical’s primary focus and service has been to combine psychedelic treatment with high and low dose ketamine psychotherapy.

Highlights of asset acquisition and future growth plans:

  • Improvement of current offers. Current treatment offerings continue to be updated with enhanced tripsitting, preparation and onboarding services for patients. Patients have access to integration specialists who have strong mental health training and advanced training in mindfulness and psychedelic integration.
  • New offers: With TripSitter.Clinic, Reconscious Medical has offered unlimited psychedelic group onboarding sessions for active patients.
  • Upcoming offers: Reconscious Medical will be instrumental in expanding TripSitter.Clinic’s services through ketamine-assisted psychotherapy, outpatient tripsitting training and psychedelic-assisted psychotherapy training programs, and one-on-one classes psychedelic coaching and psychotherapy. Reconscious Medical will play a vital role in developing safe and effective treatment protocols for patients in need of mental health treatment.
  • Technology platform. Reconscious Medical will integrate its technology platform created specifically for virtual psychedelic psychotherapy with TripSitter.Clinic’s state-of-the-art telehealth system. The combined technology will be the foundation for safe and transformational healing for patients.

The Society is also pleased to announce the appointment of Dr. Marc Braunstein as Chairman of the Board of Directors replacing Mr. Richard Dolan who resigned August 19, 2022. Dr. Braunstein commented, “I am delighted to join the Tripsitter Board of Directors as Chairman. Combining Tripsitter’s technology platform with Reconcious Medical’s world-class protocols will allow us to reach more people in need of healing.

dr. Marc Braunstein

Dr. Braunstein is first and foremost an integrative psychiatrist. He completed his residency in general psychiatry and fellowship in child and adolescent psychiatry in 1997. Soon after, he began to explore the use of herbal psychoactive medications in the treatment of various psychiatric conditions in children and adults. With over 22 years of clinical experience, Dr. B has pioneered a new path in psychiatric care that incorporates wilderness programming, exercise, diet, spirituality, and natural medicines. All with a focus on psychedelic theory. Dr. B is the medical director of several psychedelic mental health clinics. His herbal dosing protocols have made him a sought-after medical consultant, counselor and educator. He directs wellness-focused inpatient and outpatient treatment programs. Driven by a passion to educate and uplift humanity to a healthier and happier place, Dr. B is involved in several projects focused on expanding access, awareness, research and safety in the field of psychedelics.


TripSitter Clinic LTD., through its wholly owned subsidiary TripSitter Clinic Corp, is at the forefront of two emerging sectors: telehealth and psychedelic medicine. The Company’s virtual advisory clinic, TripSitter.Clinic, is an internationally renowned SaaS platform that provides care, monitoring and coaching while connecting patients with licensed physicians in United States who can evaluate a prescribed psychedelic treatment program of low dose ketamine therapeutic drugs. TripSitter is not a primary care physician (PCP). TripSitter.Clinic requires prospective patients to provide a diagnosis of their PCP along with other health information to their chosen TripSitter physician during the initial intake process. When a patient is approved for treatment by their doctor, TripSitter.Clinic connects the patient with experts who also use the platform to consult and coordinate with the patient and their doctor. Learn more about


Reconscious Medical (RM) is a psychedelic psychotherapy company established in 2020 with Dr. Marc Braunstein and co-founder Matthew Campeau, LPC to expand access to psychedelic psychotherapies through technology. RM offers three main products. The first is clinic-intensive psychedelic psychotherapy using high-dose (IM and oral) ketamine-assisted psychotherapy (KAP) sessions. The second is the most scalable being virtual Low Dose Ketamine (Oral) Enhanced Psychotherapy (KEP) sessions The third is a technology platform that acts as a delivery system for the virtual model as well as the health record (EHR) for clinical work. Reconscious Medical excels in the development and implementation of state-of-the-art psychedelic therapy protocols as well as proprietary screening and dosing algorithms. RM also trains therapists, babysitters, integration specialists and doctors.


dr. John HuberCEO
[email protected]

The Canadian Securities Exchange has neither approved nor disapproved of the contents of this press release and accepts no responsibility for the adequacy or accuracy of this release.

Disclaimer for forward-looking information

This press release contains certain forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “goal”, “may”, “will”, “project”, “should”, “believe ”, “plan”, “intends” and similar expressions are intended to identify forward-looking information or statements. Forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on forward-looking statements and information as the Company cannot give any assurance that they will prove to be correct. . Because forward-looking statements and information relate to future events and conditions, they, by their very nature, involve inherent risks and uncertainties. Forward-looking information in this press release includes statements regarding the company’s general business plans, the telehealth industry and the company’s market position within it, as well as statements regarding the of the company’s ordinary shares on the CSE. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors that could materially affect such forward-looking information are described in the risk factors in the Company’s final long form prospectus dated November 22, 2021and the related schedules, which are available on the Company’s profile on SEDAR at Readers are cautioned that the above list of factors is not exhaustive. The forward-looking statements included in this press release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this press release are made as of the date hereof, and the Company undertakes no obligation to publicly update or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise. , except as required by applicable law.


Show original content to download multimedia: braunstein-as-president-301675532.html

SOURCE TripSitter Clinic Ltd.


Comments are closed.